Drug Trial Radar · NCT03997383
APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
Last checked: Nov 19, 2026Latest source record: Apr 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
360
Actual
Start
Sep 4, 2019
Primary completion
Jun 20, 2022
Study completion Dec 24, 2025
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- Jun 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of patisiran in participants with ATTR amyloidosis with cardiomyopathy.
Conditions
- Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions
PlaceboDrug
Normal saline (0.9% NaCl) matching volume of patisiran doses will be administered intravenously.
PatisiranDrug
Patisiran will be administered by intravenous (IV) infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline at Month 12 in Six-Minute Walk Test (6-MWT)Time frame: Baseline, Month 12
Locations
90 sites in 22 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Los Angeles, California
Clinical Trial Site
Chicago, Illinois
Clinical Trial Site
Skokie, Illinois
Clinical Trial Site
Iowa City, Iowa
Clinical Trial Site
Kansas City, Kansas
Clinical Trial Site
Baltimore, Maryland
Clinical Trial Site
Boston, Massachusetts
Clinical Trial Site
Burlington, Massachusetts
Clinical Trial Site
Rochester, Minnesota
Clinical Trial Site
St Louis, Missouri
Clinical Trial Site
New York, New York
Clinical Trial Site
New York, New York
Clinical Trial Site
Cleveland, Ohio
Clinical Trial Site
Philadelphia, Pennsylvania
Clinical Trial Site
Philadelphia, Pennsylvania
Clinical Trial Site
Pittsburgh, Pennsylvania
Clinical Trial Site
Nashville, Tennessee
Clinical Trial Site
Dallas, Texas
Clinical Trial Site
Norfolk, Virginia
Clinical Trial Site
Buenos Aires, Argentina
Clinical Trial Site
Buenos Aires, Argentina
Clinical Trial Site
Córdoba, Argentina
Clinical Trial Site
Rosario, Argentina
Clinical Trial Site
Rosario, Argentina
Clinical Trial Site
Rosario, Argentina
Clinical Trial Site
San Juan Bautista, Argentina
Clinical Trial Site
Santa Fe, Argentina
Clinical Trial Site
Box Hill, Australia
Clinical Trial Site
Westmead, Australia
Clinical Trial Site
Woolloongabba, Australia
Clinical Trial Site
Aalst, Belgium
Clinical Trial Site
Hasselt, Belgium
Clinical Trial Site
Liège, Belgium
Clinical Trial Site
Roeselare, Belgium
Clinical Trial Site
Porto Alegre, Brazil
Clinical Trial Site
Ribeirão Preto, Brazil
Clinical Trial Site
Ribeirão Preto, Brazil
Clinical Trial Site
Rio de Janeiro, Brazil
Clinical Trial Site
São Paulo, Brazil
Clinical Trial Site
São Paulo, Brazil
Showing 40 of 90 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.